Solid Biosciences announced a non‑exclusive worldwide license and collaboration with Andelyn Biosciences, a contract development and manufacturing organization that specializes in cell and gene therapies. The agreement gives Andelyn the right to use Solid’s proprietary AAV‑SLB101 capsid in its gene‑therapy clients, integrating the capsid with Andelyn’s AAV Curator® Platform for modular manufacturing and CMC optimization.
AAV‑SLB101 is a rationally designed capsid that delivers more than twice the skeletal and cardiac muscle tropism of first‑generation AAV9 while reducing liver biodistribution. In the Phase 1/2 INSPIRE DMD trial, 23 participants received the vector, and the study reached its safety cutoff date of October 31, 2025. The trial demonstrated robust microdystrophin expression and a favorable safety profile, providing clinical validation that underpins the commercial potential of the capsid.
For Solid, the license expands a technology that already has over 30 agreements and licenses in place. By out‑licensing AAV‑SLB101, Solid can focus on its core precision‑medicine pipeline—such as SGT‑003 for Duchenne muscular dystrophy—while generating incremental revenue through licensing fees, milestone payments, and future royalties. The deal also broadens Solid’s market reach, allowing the capsid to be deployed in early‑stage gene‑therapy programs that require efficient muscle targeting.
Andelyn benefits by adding a clinically validated, next‑generation capsid to its AAV Curator® Platform. The partnership gives Andelyn’s gene‑therapy clients access to a capsid with proven muscle‑targeting performance, potentially accelerating development timelines and providing a competitive edge in the CDMO market. While specific client names were not disclosed, the collaboration is expected to enhance Andelyn’s service portfolio across neuromuscular and cardiac indications.
Bo Cumbo, President and CEO of Solid, said the partnership “reflects our shared mission to accelerate the next generation of gene therapies built upon cutting‑edge technologies designed to enhance safety and efficacy.” Matt Niloff, Chief Commercial Officer of Andelyn, noted that the collaboration will provide clients with access to a clinically validated technology that can shorten development timelines and open new revenue streams for both companies.
No immediate market‑reaction data are available, but analysts continue to view Solid’s licensing strategy positively, citing the company’s strong pipeline and the growing demand for advanced AAV capsids. The partnership reinforces Solid’s position as a leading provider of precision gene‑therapy platforms and underscores Andelyn’s commitment to delivering high‑quality manufacturing solutions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.